Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Palmer
Pennsylvania State Univ Hershey Med Ctr, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Penn State Research Foundation
Other : Intellectual property rights (e.g., royalties, patents, copyrights)
Dr. Palmer is a co-inventor on the Penn State Research Foundation (PSRF)-held patent “Methods for Predicting and Treating Necrotizing Enterocolitis in the Preterm Neonate.” There is no associated company and there is no commercial product at this point. As there is no related equity interest, and the patent has not produced income, this is only considered a Significant Financial Interest (SFI) because there is related human subjects research. There is the potential for future royalties from the invention, and the research develops/evaluates the technology.
Although the Intellectual Property rights are held with Penn State Research Foundation (associated with the awardee institution), Penn State University policy does not exclude Penn State-owned intellectual property from the definition of Significant Financial Interest. Additionally, although there has been no revenue from the intellectual property, the College of Medicine Conflict of Interest Review Committee reviews any intellectual property rights, regardless of value, if related to human subjects research.
Vagal Dysregulation in Neonatal Gastrointestinal Pathology
Necrotizing enterocolitis (NEC) is one of the most common and damaging diseases in the neonatal intensive care unit (NICU), affecting 6-10% of preterm infants with a mortality rate of 15-25% and an estimated burden to the US healthcare system of $500million - $1billion annually. A non-invasive, easy to obtain, inexpensive predictive biomarker that allows the early detection of NEC is required as a matter of urgency. The present project will adopt a translational approach, combining clinical and basic research, to identify i) non-invasive biomarkers predictive of NEC, ii) the cellular mechanisms behind these predictive biomarkers and iii) to develop targeted interventions to reduce the adverse outcome associated with NEC
Filed on June 05, 2019.
Tell us what you know about Charles Palmer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.